MKI67 and neoplasm: Specifically, patients in risk group 1 (n = 20) had low expression of Ki-67(≤50%), and low clinical tumor stage (≤3) and nodal stage (≤1), whereas risk group 2 (n = 30) included any patient with high expressions/values of Ki-67, pT, or pN.